Members of the transforming growth factor beta (TGF-beta) family regulate fundamental physiological process, such as cell growth, differentiation and apoptosis. As a result, defects in this pathway have been linked to uncontrolled proliferation and cancer progression. Here we explore the signal transduction mechanism of TGF-beta focusing on therapeutic intervention in human diseases. Like TGF-beta, another member of the TGF-beta superfamily, activin has been proven to play an important role in maintenance of tissue homeostasis and dysregulation leads to disease. Several studies showed elevated levels of activin are responsible for the development of gonadal tumours and a cachexia-like weight loss syndrome. Discussing the recent advances in approaches developed to antagonise the activin pathway and the encouraging results obtained in animal models, this review presents a therapeutic rationale for targeting the activin pathway in conditions such as cachexia, neuromuscular and/or musculoskeletal disorders.
Marino, F. E., Risbridger, G. P., & Gold, E. (2013). The therapeutic potential of blocking the activin signalling pathway. Cytokine and Growth Factor Reviews, 24(5), 477 - 484. https://doi.org/10.1016/j.cytogfr.2013.04.006